Sumitomo Pharma Co

Sumitomo Pharma Co PEG

The PEG Ratio (Price/Earnings-to-Growth) of Sumitomo Pharma Co (4506.T) as of Nov 4, 2026 is 0.02. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 0.32 — a change of -92.39% (lower).

PEG

0.02

YoY

-92.39%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Sumitomo Pharma Co is 2026 0.02 . PEG Ratio (Price/Earnings-to-Growth) of Sumitomo Pharma Co was 2025 0.32 . It decreases by -92.39% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sumitomo Pharma Co Stock analysis

What does Sumitomo Pharma Co do? Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sumitomo Pharma Co stock

PEG Ratio (Price/Earnings-to-Growth) of Sumitomo Pharma Co is 0.02 in 2026.

PEG Ratio (Price/Earnings-to-Growth) of Sumitomo Pharma Co changed from 0.32 to 0.02, representing a -92.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Sumitomo Pharma Co since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Sumitomo Pharma Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Sumitomo Pharma Co

All Key Metrics — Sumitomo Pharma Co